Navigation Links
PTS, Inc. Announces Two New Patents
Date:7/10/2013

INDIANAPOLIS, July 10, 2013 /PRNewswire/ -- Polymer Technology Systems, Inc. (PTS, Inc.), the U.S.-based manufacturer of the CardioChek® family of point-of-care diagnostic products, has announced the issuance of two new U.S. patents.  U.S. Patent No. 8,257,654 relates to the management of health data collected by point-of-care testing devices using a health report server.  U.S. Patent No. 8,307,531 covers a method and apparatus for manufacturing disposable dry test strips. 

"Our products are built upon a number of proprietary technologies and processes," says Robert Huffstodt, President and CEO of PTS, Inc.  "These patents, along with the other patents we hold, help PTS, Inc. maintain technological leadership for our customers."

U.S. Patent No. 8,257,654 is for a health report server that may receive medical data from a diverse set of point-of-care testing systems deployed in a hospital or other medical facility.  By utilizing a network-based system, medical data can be collected concerning patients and then securely and conveniently stored.  The system allows for medical data to then be distributed to those medical personnel who need it, such as doctors.  The system provides for simple menu-driven access to the stored medical information. 

PTS, Inc. has led the way in providing innovative connectivity solutions.  For example, the CardioChek HRA software captures biometric data and receives test results directly from a CardioChek PA analyzer to calculate a cardiac age based on an individual's risk factors using the Framingham Heart Study criteria.  And, CardioChek Link® data transfer software and cable provides for the output of test results from the CardioChek PA device into a computer spreadsheet file.

The intellectual property covered under U.S. Patent No. 8,307,531 not only provides for a m
'/>"/>

SOURCE Polymer Technology Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Neurotechnology Announces MegaMatcher Accelerator 6.0 High-speed, High-volume Multibiometric Identification Solution and Updates to Entire Biometric Product Line
2. Xyngular Announces the Launch of its New Xyng Enhanced Formula
3. Wiley announces increase in Impact Factors
4. PatientStream announces the industrys first Multilingual family waiting room board
5. DigitalPersona Announces U.are.U Software Development Kit (SDK) for Android Applications
6. Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics
7. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
8. Missouri Botanical Garden program announces collaboration with LHerboretum
9. DFG announces recipients of 2013 Heinz Maier-Leibnitz Prize
10. PLOS announces Accelerating Science Award Program
11. AAPS announces 2013 National Biotechnology Conference award winners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... As drylands of the world become even drier, water will not ... the soil will likely be affected, and their imbalance could affect ... That includes people living in Arizona, who may be in for ... study published in Nature that details how soil changes ...
... teams at the Polytechnic Institute of New York University ... understand and influence the complex swimming behaviors of schooling ... of mechanical and aerospace engineering at NYU-Poly, published two ... These studies are the latest in a ...
... scent marking to advertise their territory they urinate at ... It has been suggested that markings serves to attract females ... males, scent marks appear to be a secondary sexual trait, ... mate. When male house mice are subordinate or sick, for ...
Cached Biology News:Plant production could decline as climate change affects soil nutrients 2The secret's in the (robotic) stroke 2The secret's in the (robotic) stroke 3Scent marking 2
(Date:5/28/2015)... , May 27, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:5/28/2015)... , May 28, 2015 Celsion Corporation ... it has received commitments from two institutional healthcare investors ... the Company,s common stock in an at-the-market registered direct ... purchase common stock. The Company entered into ... which the Company agreed to sell an aggregate of ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Glenn Keet, ... The Changing Landscape of EMR/EHR Clinical Data Integration with ... taking place in Washington, DC on June 14th-18th. , ... of integrating EMR/EHR systems with EDC, and will examine ... brought by eSource and electronic health records/electronic medical records ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... Visionsense Corp. announces,FDA 510(k) Clearance of ... The system is based on a miniature ... Minimal Invasive,laparoscopic and endoscopic Surgery (MIS)., ... MIS surgical,procedures that are under served by ...
... Therapeutics announced today,the initiation of a Phase ... orally bioavailable small molecule in development for ... I study will evaluate the safety,tolerability and ... blind, placebo controlled, single ascending dose design ...
... March 18 TorreyPines Therapeutics,Inc. (Nasdaq: TPTX ... II study of,NGX267, a muscarinic agonist in development ... The company is conducting a randomized, double-blind,placebo-controlled, ... evaluate,the safety, tolerability and efficacy of this once-a-day ...
Cached Biology Technology:Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Biology Products: